Oral rheumatoid arthritis therapy, Xeljanz, attempting for insurance as secondary treatment
An oral rheumatoid arthritis treatment ‘Xeljanz’ starts a move to recover its position as a practical secondary treatment.
According to the industry concerned on the 12th, the Pfizer’s janus kinase(JAK) inhibitor Xeljanz(tofacitinib) which failed in the last year’s extension of the health insur...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
